Top accelerator startups

14,448 startups · 29 programs

Guardian Bio

Active · Dendritic cell-based platform for cancer therapy

7signal of 100 · rising 2
  • went through YCProgram · this site+4
  • team of 2Team size · YC's directory+2.5

A sum of public facts, not a judgement and not investment advice.

Competitors

Adjacent

Also from S22

All of S22

About Guardian Bio

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. Our therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.

YC batch
S22 · Summer 2022
Status, per YC
Active
Category
Other
Team size
2
Location
Boston, MA, USA
Checked
10h ago

YC tags: Biotech, Healthcare, Therapeutics, Oncology

Guardian Bio in S22: 233 companies, 54% AI

Guardian Bio: questions

Which YC batch was Guardian Bio in?

Guardian Bio was in Y Combinator's Summer 2022 batch (S22).

Is Guardian Bio still active?

Y Combinator lists Guardian Bio as active.

Where is Guardian Bio based?

Guardian Bio lists Boston, MA, USA as its location on YC's directory.